Clinical Trials

6,720 enrolled

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04181827 2026-04-13

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT04923893 2026-04-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

281 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04975997 2026-04-03

EXCALIBER-RRMM

939 enrolled

Multiple Myeloma

NCT05552976 2026-04-01

SUCCESSOR-2

606 enrolled

Multiple Myeloma, Recurrence

NCT01190930 2026-03-31

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

9,350 enrolled 51 charts

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04162210 2026-03-31

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT02845882 2026-03-18

LBL-2016 for Children or Adolescents in China

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

125 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05257083 2026-03-17

CARTITUDE-6

759 enrolled

Multiple Myeloma

NCT02659293 2026-03-04

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

180 enrolled

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

250 enrolled

Multiple Myeloma

NCT03007147 2026-02-23

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

475 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 2 FDA

Multiple Myeloma

NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

270 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

177 enrolled

Multiple Myeloma

NCT03617731 2026-02-03

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

662 enrolled

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03020030 2026-01-22

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

560 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

337 enrolled

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

117 enrolled

Multiple Myeloma

NCT02101853 2025-12-01

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

669 enrolled 14 charts

Lymphoid

Burkitt Lymphoma

NCT02112916 2025-12-01

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

847 enrolled 19 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02003222 2025-11-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

488 enrolled 13 charts 2 FDA

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02883049 2025-11-26

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

5,949 enrolled 28 charts

Lymphoid

Burkitt Lymphoma

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

245 enrolled 15 charts 2 FDA

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT01863550 2025-09-08

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

1,087 enrolled

Multiple Myeloma

NCT00734877 2025-06-29

TT4B

382 enrolled

Multiple Myeloma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT06956170 2025-06-11

DREAMM 8

21 enrolled 9 charts

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

24 enrolled 10 charts

Multiple Myeloma

NCT06868654 2025-04-23

DREAMM 7

72 enrolled 10 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

302 enrolled 10 charts

Multiple Myeloma

NCT04096066 2025-01-15

KRdvsRd

84 enrolled

Multiple Myeloma

NCT03836014 2024-12-06

CONFIRM

436 enrolled

Multiple Myeloma, Recurrence

NCT03319667 2024-11-27

IMROZ

475 enrolled 3 FDA

Multiple Myeloma

NCT04934475 2024-11-07

MIDAS

791 enrolled

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

494 enrolled 10 charts 3 FDA

Multiple Myeloma

NCT03948035 2023-05-06

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

576 enrolled

Multiple Myeloma

NCT02544308 2022-12-23

IDRIS

36 enrolled

Plasmacytoma

NCT03651128 2022-12-15

KarMMa-3

381 enrolled